Edralbrutinib

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 535191

CAS#: 1858206-58-2

Description: Edralbrutinib, also known as TG-1701, is a Bruton's tyrosine kinase inhibitor. Antitumor Activity of TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. TG-1701 is as active as ibrutinib but with improved selectivity. TG-1701, in contrast to ibrutinib, does not block neither ublituximab-driven ADCC nor ADCP in vitro. In vivo xenograft studies suggested that TG-1701 synergized with ublituximab and umbralisib. Part of the mechanism is related to the pro-immune interleukin signature and infiltration of NK cells in the tumor.

Chemical Structure

img
Edralbrutinib
CAS# 1858206-58-2
Instruction

Theoretical Analysis

MedKoo Cat#: 535191
Name: Edralbrutinib
CAS#: 1858206-58-2
Chemical Formula: C26H21F2N5O3
Exact Mass: 489.16
Molecular Weight: 489.483
Elemental Analysis: C, 63.80; H, 4.32; F, 7.76; N, 14.31; O, 9.81

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Edralbrutinib; TG-1701; TG 1701; TG1701;

IUPAC/Chemical Name: 4-amino-1-[(3R)-1-(but-2-ynoyl)pyrrolidin-3-yl]-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-7Hpyrrolo[2,3-d]pyridazin-7-one

InChi Key: DNPOFZXZJJDQLB-MRXNPFEDSA-N

InChi Code: InChI=1S/C26H21F2N5O3/c1-2-4-21(34)32-12-11-16(13-32)33-14-18(22-23(33)26(35)31-30-25(22)29)15-7-9-17(10-8-15)36-24-19(27)5-3-6-20(24)28/h3,5-10,14,16H,11-13H2,1H3,(H2,29,30)(H,31,35)/t16-/m1/s1

SMILES Code: O=C1C(N([C@H]2CN(C(C#CC)=O)CC2)C=C3C4=CC=C(OC5=C(F)C=CC=C5F)C=C4)=C3C(N)=NN1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 489.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Ribeiro ML, Reyes-Garau D, Vinyoles M, Profitós Pelejà N, Santos JC, Armengol M, Fernández-Serrano M, Sedó Mor A, Bech-Serra JJ, Blecua P, Musulen E, De La Torre C, Miskin H, Esteller M, Bosch F, Menéndez P, Normant E, Roué G. Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Dec 1;27(23):6591-6601. doi: 10.1158/1078-0432.CCR-21-1067. Epub 2021 Sep 22. PMID: 34551904.